AR007096A1 - Compuesto inhibidor de la metaloproteasa de matriz metodo para inhibir su actividad, una composicion que lo contiene y uso de dichos compuestos para preparar composiciones farmaceuticas - Google Patents
Compuesto inhibidor de la metaloproteasa de matriz metodo para inhibir su actividad, una composicion que lo contiene y uso de dichos compuestos para preparar composiciones farmaceuticasInfo
- Publication number
- AR007096A1 AR007096A1 ARP970101976A ARP970101976A AR007096A1 AR 007096 A1 AR007096 A1 AR 007096A1 AR P970101976 A ARP970101976 A AR P970101976A AR P970101976 A ARP970101976 A AR P970101976A AR 007096 A1 AR007096 A1 AR 007096A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- activity
- pharmaceutical compositions
- formula
- inhibiting
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 230000000694 effects Effects 0.000 title abstract 4
- 239000011159 matrix material Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 102000002274 Matrix Metalloproteinases Human genes 0.000 abstract 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 206010053555 Arthritis bacterial Diseases 0.000 abstract 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 abstract 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 abstract 1
- 208000016192 Demyelinating disease Diseases 0.000 abstract 1
- 206010053177 Epidermolysis Diseases 0.000 abstract 1
- 208000004575 Infectious Arthritis Diseases 0.000 abstract 1
- 206010060820 Joint injury Diseases 0.000 abstract 1
- 208000029725 Metabolic bone disease Diseases 0.000 abstract 1
- 102000005741 Metalloproteases Human genes 0.000 abstract 1
- 108010006035 Metalloproteases Proteins 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000028911 Temporomandibular Joint disease Diseases 0.000 abstract 1
- 208000007474 aortic aneurysm Diseases 0.000 abstract 1
- 210000000845 cartilage Anatomy 0.000 abstract 1
- 201000007717 corneal ulcer Diseases 0.000 abstract 1
- 208000002528 coronary thrombosis Diseases 0.000 abstract 1
- 230000003412 degenerative effect Effects 0.000 abstract 1
- 150000004820 halides Chemical class 0.000 abstract 1
- 230000028709 inflammatory response Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 210000000653 nervous system Anatomy 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 208000028169 periodontal disease Diseases 0.000 abstract 1
- 201000001474 proteinuria Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 201000001223 septic arthritis Diseases 0.000 abstract 1
- 230000000472 traumatic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Steroid Compounds (AREA)
Abstract
Presenta compuestos que tienen la fórmula (I), donde y es 0, 2 o 3; r es 0-6, Z es (CH2)7- o (CH2)e-C6H4-(CH2)f o donde e es 0-1 y f es 1-6; R15 esH, -Cl, -OMe o de fórmula (II), donde n es 0-4, R17 es C2H5, -alilo, o -bencilo, y R16 esd e fórmula (III), donde t es 0-1, x es 0-4 y R4 es unode los siguientes: haluro, alquilo de 1 a 6 carbonos, OR, NR2, NO2(R=H o alquilo de 1 a 6 carbonos). Estos compuestos son útiles para inhibir lasmetaloproteasas de matriz y, por lo tanto,pa ra combatir los trastornos a los cuales contribuyen las MMP, tales como la osteoartritis, la artritisreumatoidea, la artritits séptica, las enfermedades periodontales, las úlceras de córnea, la proteinuria, la enfermedad deaneurisma a órtico, laepidermólisis vesicular distrófica, los trastornos que producen respuestas inflamatorias, las osteopenias en las que media la actividad de MMP, laenfermedad de la articulación temporomandibular, las enfermedades desmielin izantes del sistema nervioso; las metástasis de tumores o lapérdida degenerativa de cartílago posterior a la lesión articular traumática, y la trombosis coronaria a partir de la ruptura de placa ateroesclerótica.Asimismo se relacionacon un método para inhibir su actividad, con composiciones farmacéuticas y uso de dichos compuestos para prepararcomposiciones farmacéuticas que comprenden una cantidad de un compuesto que sea eficaz para inhibir la actividad de porlo menos una m etaloproteasa dematriz.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64838496A | 1996-05-15 | 1996-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR007096A1 true AR007096A1 (es) | 1999-10-13 |
Family
ID=24600568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970101976A AR007096A1 (es) | 1996-05-15 | 1997-05-12 | Compuesto inhibidor de la metaloproteasa de matriz metodo para inhibir su actividad, una composicion que lo contiene y uso de dichos compuestos para preparar composiciones farmaceuticas |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP0912487A1 (es) |
| JP (1) | JP3417951B2 (es) |
| CN (1) | CN1163466C (es) |
| AR (1) | AR007096A1 (es) |
| AU (1) | AU727648B2 (es) |
| CA (1) | CA2253869C (es) |
| CO (1) | CO4990925A1 (es) |
| HR (1) | HRP970246B1 (es) |
| ID (1) | ID20291A (es) |
| MY (1) | MY132470A (es) |
| PA (1) | PA8429401A1 (es) |
| PE (1) | PE65998A1 (es) |
| SV (1) | SV1997000034A (es) |
| TN (1) | TNSN97085A1 (es) |
| TW (1) | TW467892B (es) |
| WO (1) | WO1997043238A1 (es) |
| YU (1) | YU18797A (es) |
| ZA (1) | ZA974032B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6288063B1 (en) | 1998-05-27 | 2001-09-11 | Bayer Corporation | Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors |
| GB0321538D0 (en) * | 2003-09-13 | 2003-10-15 | Glaxo Group Ltd | Therapeutically useful compounds |
| EP2184284B1 (en) * | 2007-08-15 | 2013-04-10 | Kyorin Pharmaceutical Co., Ltd. | Preventive, inhibitor or remedy for cerebral aneurysm comprising ibudilast as an active ingredient |
| JP2017509665A (ja) | 2014-04-03 | 2017-04-06 | バイエル ファーマ アクチエンゲゼルシャフト | 気道疾患治療のための２，５−ジ置換されたシクロペンタンカルボン酸類 |
| US20170022171A1 (en) | 2014-04-03 | 2017-01-26 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituted cyclopentanecarboxylic acids and their use |
| US20170119776A1 (en) | 2014-04-03 | 2017-05-04 | Bayer Pharma Aktiengesellschaft | Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3827324B2 (ja) * | 1994-01-22 | 2006-09-27 | ブリテッシュ バイオテック ファーマシューティカルズ リミテッド | 金属タンパク質分解酵素阻害剤 |
| ATE214368T1 (de) | 1995-12-22 | 2002-03-15 | Warner Lambert Co | Aromatische keto-säure und ihre derivate als inhibitoren der matrix metalloproteinase |
| CO5011071A1 (es) | 1996-05-15 | 2001-02-28 | Bayer Corp | Inhibicion de las metaloproteinasas de matriz por acidos 2-(w/aroilalquil)-4-biaril-4-oxobutiricos y composiciones farmaceuticas que los contienen |
-
1997
- 1997-05-09 HR HR970246A patent/HRP970246B1/xx not_active IP Right Cessation
- 1997-05-09 TN TNTNSN97085A patent/TNSN97085A1/fr unknown
- 1997-05-09 CO CO97025164A patent/CO4990925A1/es unknown
- 1997-05-09 MY MYPI97002045A patent/MY132470A/en unknown
- 1997-05-09 ZA ZA9704032A patent/ZA974032B/xx unknown
- 1997-05-12 TW TW086106284A patent/TW467892B/zh not_active IP Right Cessation
- 1997-05-12 AU AU31219/97A patent/AU727648B2/en not_active Ceased
- 1997-05-12 WO PCT/US1997/007975 patent/WO1997043238A1/en not_active Ceased
- 1997-05-12 PE PE1997000362A patent/PE65998A1/es not_active Application Discontinuation
- 1997-05-12 AR ARP970101976A patent/AR007096A1/es unknown
- 1997-05-12 CA CA002253869A patent/CA2253869C/en not_active Expired - Fee Related
- 1997-05-12 CN CNB971964599A patent/CN1163466C/zh not_active Expired - Fee Related
- 1997-05-12 PA PA19978429401A patent/PA8429401A1/es unknown
- 1997-05-12 JP JP54100297A patent/JP3417951B2/ja not_active Expired - Fee Related
- 1997-05-12 EP EP97926454A patent/EP0912487A1/en not_active Withdrawn
- 1997-05-12 SV SV1997000034A patent/SV1997000034A/es not_active Application Discontinuation
- 1997-05-12 YU YU18797A patent/YU18797A/sr unknown
- 1997-05-14 ID IDP971607A patent/ID20291A/id unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU727648B2 (en) | 2000-12-21 |
| CN1225622A (zh) | 1999-08-11 |
| ID20291A (id) | 1998-11-19 |
| ZA974032B (en) | 1998-02-19 |
| CA2253869C (en) | 2003-04-22 |
| AU3121997A (en) | 1997-12-05 |
| CO4990925A1 (es) | 2000-12-26 |
| HRP970246A2 (en) | 1998-04-30 |
| MY132470A (en) | 2007-10-31 |
| PE65998A1 (es) | 1998-10-20 |
| TNSN97085A1 (fr) | 2005-03-15 |
| YU18797A (en) | 1999-11-22 |
| JPH11509870A (ja) | 1999-08-31 |
| EP0912487A1 (en) | 1999-05-06 |
| WO1997043238A1 (en) | 1997-11-20 |
| TW467892B (en) | 2001-12-11 |
| PA8429401A1 (es) | 2000-05-24 |
| SV1997000034A (es) | 1999-07-05 |
| CN1163466C (zh) | 2004-08-25 |
| JP3417951B2 (ja) | 2003-06-16 |
| HRP970246B1 (en) | 2002-04-30 |
| CA2253869A1 (en) | 1997-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE89263T1 (de) | Naphthalin-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen. | |
| FI971312A0 (fi) | Uudet prostaglandiinisyntaasin estäjät | |
| ATE25974T1 (de) | Acyl-substituierte derivate von 1,2,3,4tetrahydroisochinolin-3-carboxysaeuren, ihre salze, diese enthaltende arzneimittel und verfahren zu ihrer herstellung. | |
| AR001999A1 (es) | Derivados de acido carboxilico y composiciones conteniendolos, utiles como inhibidores de metaloproteasa de matriz, y procesos para su preparacion. | |
| DK198191A (da) | Chlorsulfat | |
| AR007098A1 (es) | Inhibidores de la metaloproteasa de matriz, composiciones que los comprenden, y uso de los mismos para preparar composiciones farmaceuticas | |
| ATE176476T1 (de) | Guanidinalkyl-1, 1-bisphosphonsäurederivate, verfahren zu ihrer herstellung und ihre verwendung | |
| AR004671A1 (es) | Nuevos compuestos en calidad de kappa-opiatagonistas y composiciones farmaceuticas que los contienen | |
| AR007096A1 (es) | Compuesto inhibidor de la metaloproteasa de matriz metodo para inhibir su actividad, una composicion que lo contiene y uso de dichos compuestos para preparar composiciones farmaceuticas | |
| BR0008778A (pt) | Análogos de prostaglandinas seletivos para fpc16 insaturados | |
| AR007100A1 (es) | Inhibicion de las metaloproteasas de matriz por compuestos de fenilalquilo sustituido y el uso de los mismos para la preparacion de un medicamento. | |
| DE3482588D1 (de) | Androstan-17beta-carbonsaeureester, ein prozess und zwischenprodukte fuer ihre herstellung, kompositionen und methode zur behandlung inflammatorischer zustaende. | |
| SV1997000038A (es) | Inhibicion de matrices metaloproteasas mediante acidos 2-(omega-aroilalkil)-4-biaril-4-oxobutirico | |
| BR9909267A (pt) | C11 oximila e prostaglandinas hidroxilamino úteis como medicamentos | |
| CA2253796A1 (en) | Inhibition of matrix metalloproteases by acetylene containing compounds | |
| RU98101090A (ru) | Моно- и дисульфозамещенные антрахиноны и их применение для лечения нарушений костного матрикса | |
| ECSP972115A (es) | Acidos oxibutiricos sustituidos como inhibidores de la metaloproteasa de matriz | |
| BR9910092A (pt) | Inibidores de beta-aminoácido substituìdo de metionina aminopeptidase-2 | |
| ECSP972112A (es) | Inhibicion de las metaloproteasas de matriz por compuestos de fenetilo sustituido | |
| ECSP972111A (es) | Inhibidores de la metaloproteinasas de matriz por acidos 2-(aroilalquil)-4 biaril-4- oxobutiricos | |
| MX9206042A (es) | Nuevos derivados de tiadiazinonas, proceso para su fabricacion y preparado farmaceutico que los contiene | |
| ECSP972114A (es) | Biarilacetilenos como inhibidores de la metaloproteasa de matriz | |
| NO963369L (no) | Nye indan-2-mercaptoacetylamid-disulfidderivater som er anvendbare som inhibitorer av enkefalinase | |
| ECSP972113A (es) | Inhibicion de las metaloproteasas de matriz por acidos biariloxobutiricos sustituidos | |
| FR2572074B1 (fr) | Derives du thiadiazole actifs sur le systeme nerveux central, procede d'obtention et compositions pharmaceutiques les contenant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |